New from #OfficialNIHR https://t.co/Ci5cXD5Adn Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer http://t.co/bIr9jx0u5V
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer http://t.co/s7ZwjAujwP
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer http://t.co/TCHCixxPta
New #Cochrane Review examines evidence for doxorubicin hydrochloride in women with relapsed ovarian #cancer http://t.co/eNqrxZFDks
New #Cochrane Review examines evidence for doxorubicin hydrochloride in women with relapsed ovarian #cancer http://t.co/eNqrxZFDks
PLD/carbo should be first-line treatment for platinum-sensitive relapsed epithelial #ovariancancer http://t.co/h2W8dB77Ko #CochraneEvidence
PLD/carbo should be first-line treatment for platinum-sensitive relapsed epithelial #ovariancancer http://t.co/h2W8dB77Ko #CochraneEvidence
PLD/carbo should be first-line treatment for platinum-sensitive relapsed epithelial #ovariancancer http://t.co/h2W8dB77Ko #CochraneEvidence
New Cochrane Review: Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer http://t.co/OFVOCrlbRt